Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database

Vallejos, Carlos S.; Gómez, Henry; Cruz, Wilder R.; Pinto, Joseph A.; Dyer, Richard; Velarde, R.; Suazo, Juan F.; Neciosup, Silvia P.; León, M.L. Villalobos; Crúz, Miguel A.; Vigil, Carlos Enrique

doi:10.3816/cbc.2010.n.038

Cited by 139 publications

(139 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first one was performed by our group at the National Cancer Institute in Peru, where Vallejos et al evaluated 1198 women with BC and found a very young appearance age (median age of 50 years old), 31.1% of stage III and 5.2% of stage IV, histologic grade 3 in 41.5% and high prevalence of TNBC (21.3%) [66]. An updated analysis of these data (n = 2226) in comparison to a Spanish series (n = 1539) found higher rates of grade I tumors, large tumor size, lymph node involvement and TNBC subtype and lower rates of lobular histology (12.5 vs 6%).…”

Section: Differences In Tumor Clinicopathological Featuresmentioning

confidence: 99%

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Castañeda

Castillo

Villarreal‐Garza

et al. 2018

Breast Cancer Manag.

View full text Add to dashboard Cite

Practice pointsr Latinas with breast cancer have been associated with lower prevalence and higher mortality rates. r The access to healthcare system for Latinas has been described as lower than for white women. r Rates of grade III and triple-negative phenotype breast cancer are higher for Latinas than for white women. r BRCA mutation prevalence appears to be higher in Latinas than white women in the American population. r Distribution of BRCA mutation differs by country in Central, Latin America or Caribbean and recurrent mutations have been described in Mexico. r Finally, evaluated information about treatment efficacy and toxicity in Latinas with breast cancer indicate similar effects than in the white race.Breast cancer is a heterogeneous and genetic disease that has variability according to ethnicity and race with respect to incidence, clinical characteristics and prognosis. The incidence of breast cancer is lower but mortality is higher in Latinas than Caucasians in the US series. Risk factors appear to have different prevalence and impact in Latinas. Breast cancer in Latinas has particular clinic-pathological features including younger age, higher rates of triple-negative subtype and advanced stages. Molecular studies find that Latinas from every region have a specific BRCA incidence and a recurrent mutation, as well as differences in activity of molecular pathways. Treatment response rates and toxicity have also been compared, and no difference was found between Latinas and other ethnic groups.

show abstract

Section: Differences In Tumor Clinicopathological Featuresmentioning

confidence: 99%

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Castañeda

Castillo

Villarreal‐Garza

et al. 2018

Breast Cancer Manag.

View full text Add to dashboard Cite

show abstract

“…Nuestros hallazgos coinciden con otros estudios (13,14) , en cuanto los carcinomas triple negativo y los HER2 tienen peores características clínicopatológicas (15,16) .…”

Section: Discussionunclassified

Características clínicas y pronosticas de los subtipos moleculares de cáncer de mama determinados por Inmunohistoquímica. Arequipa, Perú

Bueno

2017

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

RESUMENCon el objetivo de determinar las características clínicas y pronósticas de los carcinomas de mama, según sus subtipos moleculares mediante la aplicación de marcadores de inmunohistoquímica, se realizó un estudio en 280 mujeres con cáncer infiltrante de mama unilateral, del 2009 al 2012. Se clasificó por técnicas de inmunohistoquímica en 4 subtipos: luminal A, luminal B, HER2 y triple negativo. Para determinar la influencia del tipo histológico y del subtipo molecular en la sobrevida global, se utilizó el método de Kaplan Meier. Se encontró que los carcinomas de mama fueron: luminal A con 105 (37,5%); luminal B con 88 (31,4%); carcinomas HER2 con 46 (16,4%), y triple negativo con 41 (14,6%). Se concluye que los carcinomas de tipo luminal fueron con mayor frecuencia tumores bien diferenciados, con ganglios axilares negativos, tamaño tumoral y estadio semejante; mientras que los tumores HER2 y triple negativo presentaron mayor proporción de tumores pobremente diferenciados, compromiso ganglionar axilar, y menor sobrevida global.Palabras clave: Neoplasias de la mama; Inmunohistoquimica; Mastectomía; Carcinoma (fuente: DeCS BIREME). CLINICAL AND PROGNOSTIC CHARACTERISTICS OF THE MOLECULAR SUBTYPES OF BREAST CANCER DETERMINED BY IMMUNOHISTOCHEMISTRY. AREQUIPA, PERU ABSTRACTThe objective of this study was to determine the clinical and prognostic characteristics of breast carcinomas according to the molecular subtype using immunohistochemical markers. The study included 280 women with unilateral breast cancer enrolled from 2009 to 2012. The carcinomas were classified into four subtypes based on immunohistochemical findings: luminal A, luminal B, HER2, and triple negative. The Kaplan-Meier test was used to determine the effect of histological type and molecular subtype on overall survival. Our results indicated that the most common breast carcinoma subtype was luminal A (105 cases, 37.5%), followed by luminal B (88 cases, 31.4%), HER2 (46 cases, 16.4%), and triple negative (41 cases, 14.6%). Luminal carcinomas were well-differentiated in most cases, without involvement of the axillary lymph nodes, and showed a similar tumor size and stage. In contrast, HER2 and triple-negative tumors were poorly differentiated in most cases, with axillary node involvement, and were associated with decreased overall survival.

show abstract

“…The hazard rate was not significantly higher in Node 6 compared with Node 5 patients (HR = 3; 95% CI: 0.7, 14; P = 0.102); however, the hazard rate in Node 8 was significantly higher than that in Node 5 (HR = 1.2; 95% CI = 1.2, 24.9, P = 0.027) and higher; yet statistically insignificant, than in Node 7 (HR = 2.5; 95% CI: 0.6, 11, P = 0.225). The event rate and estimated mean DFS for nodes 5,6, and 7 are shown in Table 2.…”

Section: Multivariate Analysismentioning

confidence: 99%

“…The treatment guidelines of breast carcinoma are based on conventional clinicopathological variables as histopathological grading, tumor size, surgical margins, and lymph node (LN) status, in addition to molecular biomarkers as hormone receptor and human epidermal growth factor receptor 2 (HER2) status [5,6].…”

Section: Introductionmentioning

confidence: 99%

Molecular Subtypes and Conventional Prognosticators for Prediction of Recurrence in a Cohort of Primary Breast Carcinoma. A Classification and Regression Trees-guided (CART-guided) Algorithm.

El-Gendi¹,

Talaat²,

Abu-Sheasha³

2017

J Interdiscipl Histopathol

View full text Add to dashboard Cite

Objectives: Surrogate immunohistochemical classification of breast carcinoma into molecular subtypes was reported to provide additional prognostic information. We aimed to investigate the prognostic value of this surrogate classification and to develop an algorithmic approach for the prediction of tumor recurrence. Materials and Methods: A retrospective cohort of 176 breast carcinomas was reclassified into the molecular subtypes using estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2)−neu and Ki-67. The significant predictors of survival as determined by bivariate analysis were entered into a Classification and Regression Tree (CART) model to identify the independent predictors. Results: CART classified the study sample according to the Ki-67 index at a cutoff of 21% into two categories with significant differences in the hazard rate. Patients whose Ki-67 was <21%, exhibited the best prognosis irrespective of the molecular subtype. Patients whose Ki-67 was ≥21% were categorized into two groups. The Luminal B HER2− patients revealed a better prognosis -that worsened if the nodes were positive or the progesterone receptor (PR) was negative or low -while Luminal B HER2+, HER2 enriched and triple negative types displayed the worst outcome, with lymphovascular invasion predicting the worst prognosis irrespective of the molecular subtype. Conclusions: Ki-67 at a cutoff value of 21% represents a reliable prognostic marker in the management of breast carcinoma patients. Low Ki-67 index (<21%) predicts the best outcome irrespective of the molecular subtype. A high Ki-67 index, combined with nodal metastasis and low PR status recognize hormone receptor positive patients with expected adverse outcome who might benefit from chemotherapy in addition to the hormonal therapy.

show abstract

Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database

Cited by 139 publications

References 20 publications

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Características clínicas y pronosticas de los subtipos moleculares de cáncer de mama determinados por Inmunohistoquímica. Arequipa, Perú

Molecular Subtypes and Conventional Prognosticators for Prediction of Recurrence in a Cohort of Primary Breast Carcinoma. A Classification and Regression Trees-guided (CART-guided) Algorithm.

Contact Info

Product

Resources

About